Presentations Covering Pentixapharm’s CXCR4 Compounds as Target for Novel Radiopharmaceuticals

The CXCR4 targeting compounds developed clinically by Pentixapharm are subject of 17 Abstracts Presentations at the 37th Annual Congress of the EANM.
The entire abstract book can be found here.

1. EPS-013: Feasibility and initial examination of chemokine receptor-4 (CXCR4) expression using 68GaPentixafor (Pars-Cixafor™) PET-MR image fusion in high-grade gliomas (HGG) H. Dadgar, B. Al-balooshi, H. Zaidi, H. Arabi, M. Assadi, M. Haidar, A. Al-Ibraheem, A. A Esmail, F. Marafi, H. AlAlawi , A. Cimini, M. Ricci

2. OP-630: 68Ga-Pentixafor PET/CT demonstrates the in vivo evidence of CXCR4 expression in radioiodine refractory thyroid cancer patients B. Singh, M. Nayeem, A. Watts, S. Bhadada

3. OP-698: The Role of 68Ga-Pentixafor PET/CT in The Diagnosis of Chronic Bone and Soft Tissue Infections. D. Denizmen Istanbul University Department of Nuclear Medicine, Istanbul, Turkey

4. OP-743: In Vivo needs in Vitro - Subtype specificity of CXCR4 Theranostics in chemotherapy resistant Muscle Invasive Bladder Cancer within the Bladder BRIDGister. R. Wirtz1 , L. Kastner, E. Storz, M. von Brandenstein, F. Friedersdorff, D. Barski, T. Otto, M. Waldner, J. Graff, E. Veltrup, F. Linden, M. Fuss, R. Hake, S. Eidt, J. Roggisch, S. Koch, C. Rieger, T. Ecke, A. Heidenreich, L. Greifenstein, R. Baum

5. OP-754: Feasibility and initial experience of chemokine receptor-4 (CXCR4) expression using 68GaPentixafor (Pars-Cixafor™) and O-2-18F-fluoroethyll-tyrosine (18F-FET) PET-MR image fusion in low and high-grade gliomas H. Dadgar, B. Al-balooshi, A. Al-Ibraheem, M. Haidar, A. A Esmail, F. Marafi, A. Cimini, H. Arabi, M. Assadi, H. Zaidi, H. Al-Alawi, M. Ricci

6. OP-785: Selective PET imaging using the Al18F-labeled CXCR4 antagonist LY2510924: “Al18F-NOTA-SC, the new kid on the block”. M. Spahn, T. Van Loy, S. Celen, M. Koole, C. Deroose, D. Schols, W. Vanduffel, G. Bormans, F. Cleeren

7. OP-833: CXCR4-targeted imaging in multiple myeloma. B. Jamet

8. OP-834: PentixaFor and PentxaTher-based Theranostics. A. Buck; Universitätsklinikum Würzburg, Dpt. of Nuclear Medicine, Würzburg, Germany.

9. OP-835: Moving towards CXCR4-targeted clinical SPECT. J. Enke; Universitätsklinikum Augsburg, Dpt. of Nuclear Medicine, Augsburg, Germany.

10. OP-836: Imaging CXCR4 expression in cardiovascular disease and inflammation. R. Werner; Universitätsklinikum Frankfurt am Main, Dpt. of Nuclear Medicine, Frankfurt, Germany

11. OP-877: Response assessment to chemotherapy in multiple myeloma by 68Ga-Pentixafor PET/CT: A comparative evaluation with18F-FDG PET/CT and IMWG based clinical response. H. Kaur, Chandigarh, India

12. EPS-190: Comparing 68Ga-Pentixafor, 18F-FDG PET/CT and chemokine receptor 4 immunohistochemistry staining in locally advanced breast cancer: a prospective cross sectional study. B. Hadebe-Chonco University of KwaZulu Natal, Durban, South Africa

13. EPS-253: Drug library screens for identifying pharmaceuticals to enhance cancer response to radioligand therapy. M. Grzmil Paul Scherrer Institute, Villigen PSI, Switzerland, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland

14. EP-0395: Preliminary comparison of 68Ga-FAPI-46 against18F-FDG, 68Ga-DOTATATE and 68Ga-Pentixafor PET/CT/MR imaging in the assessment of various cancer types. H. Dadgar Nuclear Medicine and Molecular imaging research center, RAZAVI Hospital, Mashad, Islamic Republic of Iran

15. EP-0558: Diagnostic value of 68Ga-Pentixafor PET/MR in Functional nodules of Primary Aldosteronism. X. Meng Xijing Hospital of Airforce Military Medical University, Xi’an, China

16. EP-0975: PET imaging of CXCR4 expression with [18F]AlFNOTA-QHY-04 in multiple tumors. S. Xu, T. Liu, S. Wang, J. Yu, J. Liu; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

17. EP-1254: Assessment of Economic Implications of CXCR4- Directed Molecular Imaging in Marginal Zone Lymphomas: A Cost-Consequence Analysis. L. Camacho, M. Kurte, C. Rupprecht, R. Dengler, W. Schlötelburg, J. Duell, A. Buck, F. Kron